Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Precision BioSciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
DTIL
Nasdaq
2836
www.precisionbiosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Precision BioSciences, Inc.
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
- Jan 29th, 2025 12:01 pm
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
- Jan 9th, 2025 3:01 pm
iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
- Jan 9th, 2025 1:00 pm
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
- Dec 19th, 2024 10:42 am
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
- Dec 18th, 2024 12:01 pm
Precision BioSciences to Participate in Upcoming November Investor Conferences
- Nov 21st, 2024 12:01 pm
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
- Nov 15th, 2024 12:00 pm
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
- Nov 4th, 2024 1:15 pm
Precision BioSciences: Q3 Earnings Snapshot
- Nov 4th, 2024 12:13 pm
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 4th, 2024 12:01 pm
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
- Nov 1st, 2024 11:43 am
Precision BioSciences to Report Third Quarter Results on November 4, 2024
- Oct 29th, 2024 11:01 am
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
- Oct 28th, 2024 11:01 am
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
- Oct 24th, 2024 8:15 pm
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
- Oct 24th, 2024 3:48 pm
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
- Oct 24th, 2024 12:47 pm
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
- Oct 21st, 2024 11:01 am
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
- Oct 16th, 2024 11:01 am
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
- Oct 4th, 2024 1:11 pm
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
- Oct 3rd, 2024 11:01 am
Scroll